Kro­nos stops work on leukemia drug; Aldeyra shares ral­ly on eczema da­ta; Atavis­tik Bio's $40M

Kro­nos Bio stops blood can­cer pro­gram: The biotech on Mon­day said Phase Ib da­ta of lan­raplenib in a mu­tat­ed sub­set of acute myeloid leukemia pa­tients do not sup­port pro­gres­sion to Phase II. But Kro­nos re­mains “open to fur­ther de­vel­op­ment” of the drug with a part­ner. It al­so an­nounced a new de­vel­op­ment can­di­date, KB-9558, that’s in IND-en­abling stud­ies for mul­ti­ple myelo­ma. Its stock $KRON was down about 15% on Tues­day morn­ing. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER